Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 17:10 ET | Source: Future Money Acquisition Corporation

Future Money Acquisition Corporation Announces Completion of $112,000,000 Initial Public Offering, Including Partial Exercise of Overallotment Option

New York, NY, March 30, 2026 (GLOBE NEWSWIRE) -- Future Money Acquisition Corporation (NASDAQ: FMACU) (the “Company”) today announced the closing of its initial public offering of 11,200,000 units...
March 30, 2026 16:50 ET | Source: GlucoTrack, Inc.

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued...
March 30, 2026 16:46 ET | Source: Artelo Biosciences

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of...
March 30, 2026 16:05 ET | Source: RenovoRx, Inc.

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data...
March 30, 2026 09:55 ET | Source: Equity Insider

A $244 Billion Arms Race Is Brewing in Cybersecurity

VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Four hostile nations are already embedded inside America's critical infrastructure, quietly pre-positioned to flip the switch during a...
March 30, 2026 09:00 ET | Source: Tempest Therapeutics

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the...
March 30, 2026 08:01 ET | Source: Aprea Therapeutics

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE)...
March 30, 2026 08:01 ET | Source: Vor Biopharma

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports...
March 30, 2026 07:02 ET | Source: Connect Biopharma Holdings Limited

Connect Biopharma Announces $20.2 Million Private Placement Financing

Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB)...
March 30, 2026 06:03 ET | Source: Arch Biopartners

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement...